Targeting of prosurvival pathways as therapeutic approaches against primary effusion lymphomas: Past, present, and future

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Granato, Marisa ^a   Santarelli, Roberta ^a   Gonnella, Roberta ^a   Farina, Antonella ^a   Trivedi, Pankaj ^a   Faggioni, Alberto ^a   Cirone, Mara ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; ANTIVIRUS AGENT;

APOPTOSIS; AUTOPHAGY; CELL ACTIVATION; CELL DEATH; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; DENDRITIC CELL; DOSE RESPONSE; ENDOPLASMIC RETICULUM STRESS; GLYCOLYSIS; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; REVIEW; VIRUS PARTICLE; VIRUS REPLICATION; DRUG EFFECTS; HUMAN HERPESVIRUS 8; LYMPHOMA, PRIMARY EFFUSION; VIROLOGY;

HERPESVIRIDAE;

ANTIVIRAL AGENTS; CELL DEATH; DENDRITIC CELLS; HERPESVIRUS 8, HUMAN; HUMANS; LYMPHOMA, PRIMARY EFFUSION;

EID: 84933073693     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/104912     Document Type: Review

References (52)

1. C. Boshoff and R. Weiss, "AIDS-related malignancies, " Nature Reviews Cancer, vol. 2, no. 5, pp. 373-382, 2002.
2. R.G.Nador, E.Cesarman, A.Chadburn et al., "Primary effusion lymphoma: a distinct clinicopathologic entity associated with theKaposi's sarcoma-associated herpes virus, " Blood, vol. 88, no. 2, pp. 645-656, 1996.
3. E. Cesarman, R. G. Nador, K. Aozasa, G. Delsol, J.W. Said, and D. M. Knowles, "Kaposi's sarcoma-associated herpesvirus in non-AIDS-related lymphomas occurring in body cavities, " The American Journal of Pathology, vol. 149, no. 1, pp. 53-57, 1996.
4. W. Fan, D. Bubman, A.Chadburn, W. J. Harrington Jr., E. Cesarman, and D. M. Knowles, "Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association, " Journal of Virology, vol. 79, no. 2, pp. 1244-1251, 2005.
5. B. Ensoli and A. Cafaro, "Novel strategies toward the development of an effective vaccine to prevent human immunodeficiency virus infection or acquired immunodeficiency virus, " AIDS Clinical Review, vol. 18, no. 4, pp. 23-61, 2000.
6. H. G. Drexler, C. Meyer, G. Gaidano, and A. Carbone, "Constitutive cytokine production by primary effusion (body cavitybased) lymphoma-derived cell lines, " Leukemia, vol. 13, no. 4, pp. 634-640, 1999.
7. L. Haddad, H. El Hajj, R. Abou-Merhi et al., "KSHV-transformed primary effusion lymphoma cells induce a VEGFdependent angiogenesis and establish functional gap junctions with endothelial cells, " Leukemia, vol. 22, no. 4, pp. 826-834, 2008.
8. K. D. Jones, Y. Aoki, Y. Chang, P. S. Moore, R. Yarchoan, and G. Tosato, "Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirusassociated infected primary effusion lymphoma cells, " Blood, vol. 94, no. 8, pp. 2871-2879, 1999.
9. J. Osborne, P. S. Moore, and Y. Chang, "KSHV-encoded viral IL-6 activatesmultiple human IL-6 signaling pathways, " Human Immunology, vol. 60, no. 10, pp. 921-927, 1999.
10. R. Yamin, N. S. Kaynan, A. Glasner et al., "The viral KSHV chemokine vMIP-II inhibits the migration of naive and activated human NK cells by antagonizing two distinct chemokine receptors, " PLoS Pathogens, vol. 9, no. 8, Article ID e1003568, 2013.
11. G.Niu, K. L.Wright, M.Huang et al., "Constitutive stat3 activity up-regulates VEGF expression and tumor angiogenesis, " Oncogene, vol. 21, no. 13, pp. 2000-2008, 2002.
12. D. A. Braun, M. Fribourg, and S. C. Sealfon, "Cytokine response is determined by duration of receptor and signal transducers and activators of transcription 3 (STAT3) activation, " The Journal of Biological Chemistry, vol. 288, no. 5, pp. 2986-2993, 2013.
13. S. Uddin, A. R. Hussain, P. S. Manogaran et al., "Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma, " Oncogene, vol. 24, no. 47, pp. 7022-7030, 2005.
14. Y. Aoki, G. M. Feldman, and G. Tosato, "Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma, " Blood, vol. 101, no. 4, pp. 1535-1542, 2003.
15. M. Cirone, L. Di Renzo, L. V. Lotti et al., "Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91, " PLoS ONE, vol. 7, no. 3, Article ID e31732, 2012.
16. A. Garufi, G. Pistritto, C. Ceci et al., "Targeting COX-2/PGE2 pathway inHIPK2 knockdown cancer cells: impact on dendritic cell maturation, " PLoS ONE, vol. 7, no. 11, Article ID e48342, 2012.
17. Y. Ma, R. Conforti, L. Aymeric et al., "How to improve the immunogenicity of chemotherapy and radiotherapy, " Cancer and Metastasis Reviews, vol. 30, no. 1, pp. 71-82, 2011.
18. T. S. Griffith and T. A. Ferguson, "Cell death in themaintenance and abrogation of tolerance: the five Ws of dying cells, " Immunity, vol. 35, no. 4, pp. 456-466, 2011.
19. U. Bharadwaj, M. Li, R. Zhang, C. Chen, and Q. Yao, "Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditionedmediumsuppress dendritic cell differentiation and activation, " Cancer Research, vol. 67, no. 11, pp. 5479-5488, 2007.
20. H. Xu, Y. Zhang, Y. Hua, T. Chen, H. Wang, and W.Wu, "IL-12 p35 silenced dendritic cells modulate immune responses by blocking IL-12 signaling through JAK-STAT pathway in T lymphocytes, " Biochemical and Biophysical Research Communications, vol. 353, no. 3, pp. 812-816, 2007.
21. S. L. Fossey, M. D. Bear, W.C.Kisseberth, M. Pennell, andC.A. London, "Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines, " BMC Cancer, vol. 11, article 125, 2011.
22. K. Arita, A. P. South, G. Hans-Filho et al., "Oncostatin M receptor- mutations underlie familial primary localized cutaneous amyloidosis, " The American Journal of Human Genetics, vol. 82, no. 1, pp. 73-80, 2008.
23. A. P. Bhatt and B. Damania, "AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV, " Frontiers in Immunology, vol. 3, Article ID Article 401, 2012.
24. C. C. Tomlinson and B. Damania, "The K1 protein of Kaposi's Sarcoma-Associated Herpesvirus activates the AKT signaling pathway, " Journal of Virology, vol. 78, no. 4, pp. 1918-1927, 2004.
25. S. Uddin, A. R. Hussain, K. A. Al-Hussein et al., "Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells, " Clinical Cancer Research, vol. 11, no. 8, pp. 3102-3108, 2005.
26. A. P. Bhatt, P. M. Bhende, S.-H. Sin, D. Roy, D. P. Dittmer, and B. Damania, "Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas, " Blood, vol. 115, no. 22, pp. 4455-4463, 2010.
27. R. Gonnella, R. Santarelli, A. Farina et al., "Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance andGLUT-1 plasmamembrane exposure in THP-1monocytic cell line, " Journal of Experimental and Clinical Cancer Research, vol. 32, no. 1, article 79, 2013.
28. S.-H. Sin, D. Roy, L. Wang et al., "Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling, " Blood, vol. 109, no. 5, pp. 2165-2173, 2007.
29. G. L. Johnson and R. Lapadat, "Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases, " Science, vol. 298, no. 5600, pp. 1911-1912, 2002.
30. R. Dai, R. Chen, and H. Li, "Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stressinduced cell cycle progression and cell death in human hepatocellular carcinoma cells, " International Journal of Oncology, vol. 34, no. 6, pp. 1749-1757, 2009.
31. M. Granato, R. Santarelli, L. V. Lotti et al., "JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells, " PLoS ONE, vol. 8, no. 9, Article ID e75965, 2013.
32. M. Raciti, L. V. Lotti, S. Valia, F. M. Pulcinelli, and L. Di Renzo, "JNK2 is activated during ER stress and promotes cell survival, " Cell Death and Disease, vol. 3, no. 11, article e429, 2012.
33. S. A. Keller, E. J. Schattner, and E. Cesarman, "Inhibition of NF-B induces apoptosis of KSHV-infected primary effusion lymphoma cells, " Blood, vol. 96, no. 7, pp. 2537-2542, 2000.
34. R. Gopalakrishnan, H. Matta, and P.M. Chaudhary, "A purine scaffold HSP90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP k13-induced NF-B, " Clinical Cancer Research, vol. 19, no. 18, pp. 5016-5026, 2013.
35. H. Matta and P. M. Chaudhary, "The proteasome inhibitor Bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells, " Cancer Biology and Therapy, vol. 4, no. 1, pp. 77-82, 2005.
36. P. G. Richardson, C. Mitsiades, T. Hideshima, and K. C. Anderson, "Bortezomib: proteasome inhibition as an effective anticancer therapy, " Annual Review of Medicine, vol. 57, pp. 33-47, 2006.
37. M.Cirone, L. Di Renzo, L. V. Lotti et al., "Activation of dendritic cells by tumor cell death, " OncoImmunology, vol. 1, no. 7, pp. 1218-1219, 2012.
38. M. Chatterjee, S. Jain, T. Stühmer et al., "STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90 and in multiple myeloma cells, which critically contribute to tumor-cell survival, " Blood, vol. 109, no. 2, pp. 720-728, 2007.
39. M. Chatterjee, M. Andrulis, T. Stühmer et al., "The PI3k/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma, " Haematologica, vol. 98, no. 7, pp. 1132-1141, 2013.
40. M. Granato, V. Lacconi, M. Peddis et al., "HSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma, " Cell Death and Disease, vol. 4, no. 7, article e730, 2013.
41. C. Higashi, C. Saji, K. Yamada et al., "The effects of heat shock protein 90 inhibitors on apoptosis and viral replication in primary effusion lymphoma cells, " Biological and Pharmaceutical Bulletin, vol. 35, no. 5, pp. 725-730, 2012.
42. U.Nayar, P.Lu, R. L.Goldsteinet al., "Targeting theHsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies, " Blood, vol. 122, no. 16, pp. 2837-2847, 2013.
43. B. Lamottke, M. Kaiser, M. Mieth et al., "The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases, " European Journal of Haematology, vol. 88, no. 5, pp. 406-415, 2012.
44. R. G. Jenner, K. Maillard, N. Cattini et al., "Kaposi's sarcomaassociated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10399-10404, 2003.
45. H.-J. Wen, Z. Yang, Y. Zhou, and C.Wood, "Enhancement of autophagy during lytic replication by the Kaposi's sarcomaassociated herpesvirus replication and transcription activator, " Journal of Virology, vol. 84, no. 15, pp. 7448-7458, 2010.
46. N. Kanarek and Y. Ben-Neriah, "Regulation of NF-B by ubiquitination and degradation of the IBs, " Immunological Reviews, vol. 246, no. 1, pp. 77-94, 2012.
47. R. Santarelli, R. Gonnella, G. Di Giovenale et al., "STAT3 activation by KSHV correlates with IL-10, IL-6 and IL-23 release and an autophagic block in dendritic cells, " Scientific Reports, vol. 4, article 4241, 2014.
48. K. Wakao, T. Watanabe, T. Takadama et al., "Sangivamycin induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells, " Biochemical and Biophysical Research Communications, vol. 444, no. 2, pp. 135-140, 2014.
49. K. W. Wen and B. Damania, "Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1, " Oncogene, vol. 29, no. 24, pp. 3532-3544, 2010.
50. W. Chen, S.-H. Sin, K.W.Wen, B. Damania, and D. P. Dittmer, "Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins, " PLoS Pathogens, vol. 8, no. 11, Article ID e1003048, 2012.
51. C. Soldani and A. I. Scovassi, "Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update, " Apoptosis, vol. 7, no. 4, pp. 321-328, 2002.
52. J. Banchereau, F. Briere, C. Caux et al., "Immunobiology of dendritic cells, " Annual Review of Immunology, vol. 18, pp. 767-811, 2000.